Positive Early Access to Medicines Scheme (EAMS) scientific opinion awarded to GBT’s voxelotor for the treatment of haemolytic anaemia due to sickle cell disease

27 January 2022 - Global Blood Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded ...

Read more →

People with chronic myeloid leukaemia granted early access to Novartis’ investigational treatment

24 January 2022 - The Medicine and Healthcare products Regulatory Agency grants positive scientific opinion on use of asciminib as 3rd-line ...

Read more →

Patients to receive new cancer drugs faster under Brexit rules shake-up

23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...

Read more →

Jyseleca (filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

18 January 2022 - Galapagos announced today that the Medicines and Healthcare products Regulatory Agency has granted a marketing authorization ...

Read more →

NICE moves: increased accessibility and flexibility for health tech

19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...

Read more →

NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer

20 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE for use in the ...

Read more →

UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile

19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...

Read more →

NICE recommends Rinvoq for psoriatic arthritis patients

10 January 2022 - The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending ...

Read more →

NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer

7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer ...

Read more →

Children and young people set to benefit from new treatment for peanut allergy

23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...

Read more →

MHRA approves licence extension for Novartis’ targeted therapy for advanced breast cancer patients in Great Britain

23 December 2021 - Piqray (alpelisib), in combination with fulvestrant, is approved for appropriate advanced breast cancer patients with a PIK3CA ...

Read more →

Deciphera announces approval of Qinlock in the United Kingdom for the treatment of fourth-line gastro-intestinal stromal tumour

21 December 2021 - Qinlock significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful ...

Read more →

NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma

17 December 2021 - The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund. ...

Read more →

NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer

16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, ...

Read more →

NICE recommends offering PrEP to people at high risk of HIV for first time

15 December 2021 - People at the highest risk of catching HIV should be offered pre-exposure prophylaxis, NICE has recommended for ...

Read more →